Cargando…

SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells

Background: The clinical application of EGFR tyrosine kinase inhibitors is always accompanied by inevitable drug resistance. However, the mechanism remains elusive. In the present study, we investigate the involvement of MAPK/SREBP1 pathway in NSCLC gefitinib resistance and evaluate the synergistic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Zhenzhen, Wang, Kai, Chen, Qiufang, Zheng, Xiulan, Song, Zhengyu, Ding, Xuansheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930422/ https://www.ncbi.nlm.nih.gov/pubmed/31897229 http://dx.doi.org/10.7150/jca.32989

Ejemplares similares

JuBei Oral Liquid Induces Mitochondria-Mediated Apoptosis in NSCLC Cells
por: Pan, Zhenzhen, et al.
Publicado: (2020)

BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells
por: Yu, Yaya, et al.
Publicado: (2023)

Icariin Prevents Extracellular Matrix Accumulation and Ameliorates Experimental Diabetic Kidney Disease by Inhibiting Oxidative Stress via GPER Mediated p62-Dependent Keap1 Degradation and Nrf2 Activation
por: Wang, Kai, et al.
Publicado: (2020)

Claudin1 decrease induced by 1,25-dihydroxy-vitamin D3 potentiates gefitinib resistance therapy through inhibiting AKT activation-mediated cancer stem-like properties in NSCLC cells
por: Jia, Zhirong, et al.
Publicado: (2022)

1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells
por: Jia, Zhirong, et al.
Publicado: (2020)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Docosahexaenoic Acid Serving As Sensitizing Agents And Gefitinib Resistance Revertants In EGFR Targeting Treatment
por: Ding, Xuansheng, et al.
Publicado: (2019)

Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer
por: Pan, Chi, et al.
Publicado: (2016)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Immediate loading on mandibular edentulous patient with SFI Bar® overdenture
por: Kim, Ha-Young, et al.
Publicado: (2011)

Licensing of Yeast Centrosome Duplication Requires Phosphoregulation of Sfi1
por: Avena, Jennifer S., et al.
Publicado: (2014)

Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer
por: Lu, Xiangdong, et al.
Publicado: (2021)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2012)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

A homology model of restriction endonuclease SfiI in complex with DNA
por: Chmiel, Agnieszka A, et al.
Publicado: (2005)

A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer
por: Zhao, Qingda, et al.
Publicado: (2020)

RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer
por: Kaneto, Naoki, et al.
Publicado: (2014)

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer
por: Wang, Hsian-Yu, et al.
Publicado: (2016)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
por: Sudo, Makoto, et al.
Publicado: (2013)

Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2013)

The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India
por: Mehta, Asmita Anilkumar, et al.
Publicado: (2013)

Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
por: Shimomura, Iwao, et al.
Publicado: (2013)

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
por: Carotenuto, Pietro, et al.
Publicado: (2011)

High voltage pulsed current stimulation of the sciatic nerve in rats: analysis by the SFI
por: Leoni, Anita Sofia Leite, et al.
Publicado: (2012)

SFyNCS detects oncogenic fusions involving non-coding sequences in cancer
por: Zhong, Xiaoming, et al.
Publicado: (2023)

SFyNCS detects oncogenic fusions involving non-coding sequences in cancer
por: Zhong, Xiaoming, et al.
Publicado: (2023)

Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
por: Sudo, Makoto, et al.
Publicado: (2014)

Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
por: Miyagi, Michihito, et al.
Publicado: (2022)

Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity
por: Kim, Mi Seong, et al.
Publicado: (2020)

Tanshinone IIA Reverses Gefitinib-Resistance In Human Non-Small-Cell Lung Cancer Via Regulation Of VEGFR/Akt Pathway
por: Wang, Rui, et al.
Publicado: (2019)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis
por: Yi, Min, et al.
Publicado: (2023)

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells
por: Zhang, Yi, et al.
Publicado: (2015)

Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells
por: Li, Jiajin, et al.
Publicado: (2016)

ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells
por: Qi, Mengfan, et al.
Publicado: (2018)

Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib‐resistant lung adenocarcinoma cells
por: Ni, Jie, et al.
Publicado: (2018)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
por: Tiseo, M, et al.
Publicado: (2010)

Management of patients with advanced non-small cell lung cancer: role of gefitinib
por: Velcheti, Vamsidhar, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_1ka54etfuctqsb4j5ji672bfd4